Skye Bioscience, Inc. — Director's Dealing 2023

Nov 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2023-11-06

Reporting Person: TYLE PRAVEEN (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-06	Stock Option (Right to Buy)	$3.50	A	14110	Acquired	2033-08-25	Common Stock (14110)	Direct

Footnotes

F1: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.